In2Gen

In2Gen is a South Korean biotechnology company specializing in the discovery and development of small molecule inhibitors targeting challenging protein-protein interactions (PPIs). The company utilizes its proprietary In-cell screening platform to identify drug candidates that can effectively modulate intracellular targets previously considered undruggable. Their primary therapeutic focus is oncology, with a pipeline targeting high-value oncogenic drivers such as KRAS and c-Myc. By leveraging their unique screening technology, In2Gen aims to provide novel therapeutic options for patients with hard-to-treat cancers. The company's approach focuses on maintaining the native cellular environment during the screening process to improve the success rate of clinical translation.